Biotechnology company that developed targeted covalent drugs using a proprietary platform to irreversibly bind and silence disease-causing proteins
Biotechnology company that developed targeted covalent drugs using a proprietary platform to irreversibly bind and silence disease-causing proteins. Its drug programs addressed diseases including cancer, autoimmune disorders, and hepatitis C. Acquired by Celgene in 2012.